References
- Ayesh R, Mitchell SC, Zhang A, Smith RL. The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ 1993;307: 655-7. https://doi.org/10.1136/bmj.307.6905.655
- van Thriel C, Schaper M, Kiesswetter E, Kleinbeck S, Juran S, Blaszkewicz M, et al. From chemosensory thresholds to whole body exposures-experimental approaches evaluating chemosensory effects of chemicals. Int Arch Occup Environ Health 2006;79: 308-21. https://doi.org/10.1007/s00420-005-0057-4
- Motika MS, Zhang J, Cashman JR. Flavin-containing monooxygenase 3 and human disease. Expert Opin Drug Metab Toxicol 2007;3:831-45. https://doi.org/10.1517/17425255.3.6.831
- Chalmers RA, Bain MD, Michelakakis H, Zschocke J, Iles RA. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J Inherit Metab Dis 2006;29:162-72. https://doi.org/10.1007/s10545-006-0158-6
- Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol 2013;85:1588-93. https://doi.org/10.1016/j.bcp.2013.03.020
- Yi HG, Lee JN, Ryu SD, Kang JH, Cha YN, Park CS. Secondary fish-odor syndrome can be acquired by nitric oxide-mediated impairment of flavin-containing monooxygenase in hepatitis B virus-infected patients. Korean J Physiol Pharmacol 2004;8:213-8.
- Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2006;46:65-100. https://doi.org/10.1146/annurev.pharmtox.46.120604.141043
- Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. Trimethylaminuria and a human FMO3 mutation database. Hum Mutat 2003;22:209-13. https://doi.org/10.1002/humu.10252
- Shimizu M, Allerston CK, Shephard EA, Yamazaki H, Phillips IR. Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. Br J Clin Pharmacol 2014;77:839-51. https://doi.org/10.1111/bcp.12240
- Christodoulou J. Trimethylaminuria: an under-recognised and socially debilitating metabolic disorder. J Paediatr Child Health 2012;48:E153-5. https://doi.org/10.1111/j.1440-1754.2010.01978.x
- Mountain H, Brisbane JM, Hooper AJ, Burnett JR, Goldblatt J. Trimethylaminuria (fish malodour syndrome): a "benign" genetic condition with major psychosocial sequelae. Med J Aust 2008;189: 468.
- Mitchell SC, Smith RL. Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos 2001;29(4 Pt 2):517-21.
- Phillips IR, Shephard EA. Primary trimethylaminuria. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle. 1993-2017.
- Messenger J, Clark S, Massick S, Bechtel M. A review of trimethylaminuria: (fish odor syndrome). J Clin Aesthet Dermatol 2013;6: 45-8.
- Manning NJ, Allen EK, Kirk RJ, Sharrard MJ, Smith EJ. Riboflavin-responsive trimethylaminuria in a patient with homocystinuria on betaine therapy. JIMD Rep 2012;5:71-5.
Cited by
- Acrolein‐induced atherogenesis by stimulation of hepatic flavin containing monooxygenase 3 and a protection from hydroxytyrosol vol.234, pp.1, 2017, https://doi.org/10.1002/jcp.26600
- Development and feasibility of the use of an assessment tool measuring treatment efficacy in patients with trimethylaminuria: A mixed methods study vol.42, pp.2, 2017, https://doi.org/10.1002/jimd.12023
- A series of simple detection systems for genetic variants of flavin-containing monooxygenase 3 (FMO3) with impaired function in Japanese subjects vol.41, pp.None, 2017, https://doi.org/10.1016/j.dmpk.2021.100420